New research from Avalere finds that despite the innovation of abuse-deterrent properties and labeling for branded opioids, Medicare Part D plan coverage for these products is declining rapidly.
Avalere recently researched the relationship between hospital participation in the 340B program and the recent trend of hospitals acquiring physician practices.
To evaluate public program spending on new medications in the drug development pipeline, Avalere projected the fiscal impact of 10 FDA breakthrough therapies to Medicare, Medicaid, and the health insurance exchanges created by the Affordable Care Act (ACA).
Cancer is a burden to patients and the healthcare system. Last year, an estimated 1.6 million new cancer cases were diagnosed in the U.S and the latest figures estimate that 13.4 million people, about 4 percent of the U.S. population, live with cancer in the U.S.1
Avalere analyses show that more than 700 ACOs already operate in the U.S.
Over the past four years, enrollment in Medicaid managed care has increased by 48 percent, with 46 million beneficiaries now receiving coverage through these plans. The government will soon update regulations that direct the plans providing this coverage.
New research from Avalere Health finds that 86% of pharmaceutical companies would invest more in studies to support the development of healthcare economic information if provided additional guidance on their ability to use this evidence with external audiences.
We recently sat down Brian Fuller to discuss the latest developments that are occurring with risk models and bundled payments.
Earlier this week, BioCentury featured guest commentary from Tanisha Carino and Reginald Williams about patient engagement.
A new analysis from Avalere finds that 17 million women ages 40 to 49 could lose their guarantee of mammogram coverage, if new breast cancer screening guidelines from the United States Preventive Services Task Force (USPSTF) are finalized.
A new report by Avalere Health published by the California HealthCare Foundation
Given the rapid evolution of the healthcare marketplace and increasing focus on delivery of value-based care, healthcare stakeholders across the spectrum are focused on appropriately managing risk.
Avalere hosts a series of webinars on “Navigating the New Dynamics of Outcomes Contracting and Risk Sharing Arrangements”. While traditional rebating and discounting terms have been a staple of industry contract negotiations, a new strategic focus is emerging on additional modes through which overall value can be measured for the wave of high-cost drugs now coming to shore.
A new report examines the scientific evidence regarding how new payment models and interventions are helping to shift the healthcare system from one that rewards volume to one that rewards value.
Recently, United Healthcare (UHC) announced that it will now cover video consultations from three platforms: Doctor on Demand™, American Well's Amwell™, and Optum's NowClinic®.
This past Monday, CMS announced the findings of a recent analysis which found that $384 million was saved over the first two years in the Pioneer ACO program. Most of the savings was accrued in the first performance year, totaling $279.7 million.
A new analysis from Avalere finds that the penalties associated with the individual mandate, which grow in 2015, might be too low to attract enrollment, particularly among middle-income, healthy individuals.
Achieving a vision of patient-centered healthcare requires multi-stakeholder collaboration each step of the way. As national attention on the use of patient-reported outcomes (PROs) grows, significant progress needs to be made to ensure that they are fairly used for accountability purposes in the context of performance-based payment models.
A new survey conducted by Avalere and the National Comprehensive Cancer Network® (NCCN®) shows that exchange plan participation by the nation's leading cancer centers is highly varied, but may be better than initial 2014 reports suggested.
Avalere Health today announced the hiring of Nancy McGee as executive vice president to head its thriving life sciences business unit.
